Enveric Biosciences, Inc. (ENVB)

NASDAQ: ENVB · IEX Real-Time Price · USD
1.72
-0.01 (-0.78%)
At close: Mar 21, 2023, 10:01 AM
1.79
+0.07 (4.07%)
After-hours: Mar 21, 2023, 4:17 PM EDT
-0.78%
Market Cap 3.57M
Revenue (ttm) n/a
Net Income (ttm) -52.10M
Shares Out 2.08M
EPS (ttm) -96.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 50,562
Open 1.72
Previous Close 1.73
Day's Range 1.70 - 1.76
52-Week Range 1.57 - 20.00
Beta 0.51
Analysts Buy
Price Target 8.67 (+404.07%)
Earnings Date Mar 30, 2023

About ENVB

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1994
Employees 23
Stock Exchange NASDAQ
Ticker Symbol ENVB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ENVB stock is "Buy." The 12-month stock price forecast is $8.67, which is an increase of 404.07% from the latest price.

Price Target
$8.67
(404.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the tr...

9 hours ago - Business Wire

Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the tr...

3 weeks ago - Business Wire

Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the tr...

3 weeks ago - Business Wire

Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the tr...

3 weeks ago - Business Wire

The 7 Most Promising Psychedelic Stocks to Buy in February

Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.

1 month ago - InvestorPlace

Enveric Biosciences to Present at the BIO CEO & Investor Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the ...

1 month ago - Business Wire

Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023"

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the ...

3 months ago - Business Wire

Enveric plans to spin off cannabinoid unit Akos Biosciences to shareholders

Enveric Biosciences ENVB, +0.65% stock rose 2.3% in premarket trades on Monday after the company said it submitted a confidential form S-1 draft registration statement with the U.S. Securities and Exc...

4 months ago - Market Watch

Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the...

4 months ago - Business Wire

Enveric Biosciences to Participate in A.G.P.'s Virtual Biotech Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (”Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the ...

4 months ago - Business Wire

Enveric Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired ...

7 months ago - Business Wire

7 Psychedelics Stocks to Buy for a Big Drug Boom

Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and...

7 months ago - InvestorPlace

7 Short-Squeeze Stocks to Put on Your Must-Watch List

The beaten-down stock market has created an opportunity for contrarian investors in short-squeeze stocks. Essentially, bearish traders must borrow the underlying securities which they are pessimistic ...

Other symbols: BWVEJHKOSSSDIGSIGA
7 months ago - InvestorPlace

Enveric Biosciences Appoints New Independent Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired ...

8 months ago - Business Wire

Enveric Biosciences Announces Closing of $8 Million Registered Direct and Private Placement Offerings, Priced at a Premium to Market Under Nasdaq Rules

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired ...

8 months ago - Business Wire

Enveric Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired ...

8 months ago - Business Wire

Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired ...

8 months ago - Business Wire

Enveric Biosciences Announces Reverse Stock Split

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired ...

8 months ago - Business Wire

Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired ...

8 months ago - Business Wire

Enveric Biosciences to Participate in Upcoming Conferences in June 2022

NAPLES, Fla. , June 8, 2022 /PRNewswire/ - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-i...

10 months ago - PRNewsWire

Enveric Biosciences to Participate in the Microdose Psychedelic Capital Conference on May 26, 2022

NAPLES, FLA , May 24, 2022 /PRNewswire/ - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-in...

10 months ago - PRNewsWire